DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Actonel (Risedronate Sodium) - Published Studies

 
 



Actonel Related Published Studies

Well-designed clinical trials related to Actonel (Risedronate)

Lipid profiles within the SABRE trial of anastrozole with and without risedronate. [2012]

Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. [2012]

Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial. [2012]

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet. [2012]

Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. [2011.07]

Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study. [2011.07]

Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. [2011.07]

Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. [2011.06]

Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. [2011.06]

Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study. [2011]

Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis. [2011]

Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study. [2010.12.18]

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. [2010.11]

Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. [2010.06.27]

The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial. [2010.03]

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. [2010.03]

Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease. [2010.03]

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. [2010.02.20]

Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. [2010.01]

Risedronate reduces intracortical porosity in women with osteoporosis. [2010.01]

A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. [2010.01]

Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial. [2010]

Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study. [2010]

Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome. [2010]

Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies. [2010]

Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. [2010]

Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo. [2010]

Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. [2009.11]

Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. [2009.11]

Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. [2009.08]

Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. [2009.07]

Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment. [2009.06]

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. [2009.04.11]

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. [2009.04]

Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. [2009.03.01]

LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men. [2009.03]

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study. [2009.02]

Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study. [2009.01]

The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study. [2009]

Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance. [2009]

Reducing hip fracture risk with risedronate in elderly women with established osteoporosis. [2009]

Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women. [2008.08]

Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study. [2008.07]

Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. [2008.07]

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. [2008.06.01]

Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial. [2008.06]

Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. [2008.06]

Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: A single-center, single-blind, six-period crossover study in healthy female subjects. [2008.05]

Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial. [2008.04]

Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia. [2008.04]

Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results. [2008.03]

Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial. [2008.03]

Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. [2008.03]

Fracture risk remains reduced one year after discontinuation of risedronate. [2008.03]

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. [2008.01]

Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial. [2008]

Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study. [2007.12]

Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. [2007.09]

Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial. [2007.09]

Weekly risedronate in kidney transplant patients with osteopenia. [2007.08]

Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty. [2007.07]

Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD). [2007.06]

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease. [2007.06]

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. [2007.03.20]

Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate. [2007.01]

The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women. [2007]

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis structural arthritis study. [2006.11]

Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. [2006.08]

Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. [2006.07]

Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. [2006.07]

Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy. [2006.06]

Between-meal risedronate does not alter bone turnover in nursing home residents. [2006.05]

Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis. [2006.04]

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. [2006.03]

Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study. [2006.01]

A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease. [2006.01]

Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis. [2006.01]

Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. [2006]

Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease. [2006]

Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial. [2005.10]

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. [2005.09.01]

Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. [2005.09]

Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease. [2005.09]

Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. [2005.08.08]

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. [2005.07]

Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women. [2005.05.01]

Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. [2005.05]

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data. [2005.04]

Risedronate therapy for prevention of hip fracture after stroke in elderly women. [2005.03.08]

The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study. [2005.02]

Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. [2005.01]

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173]. [2005]

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis. [2004.12]

Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis. [2004.12]

Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. [2004.11]

Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. [2004.09]

The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits. [2004.08]

Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations. [2004.07.19]

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis. [2004.05]

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. [2004.04]

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. [2004.02]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012